Foresight Diagnostics
Sandra Horning is currently a Scientific Advisory Board Member at Foresight Diagnostics. Prior to this, they were with Moderna, EQRx, and Genentech/Roche. Sandra spent September 2009 to December 2019 at Genentech/Roche as Executive Vice President, Chief Medical Officer, Global Head of Product Development. Sandra Horning has also been with Stanford University School of Medicine in the past.
Sandra Horning has a post-graduate fellowship in oncology and cancer biology from Stanford University. Sandra also has a degree from the University of Iowa School of Medicine.
This person is not in the org chart
This person is not in any offices
Foresight Diagnostics
1 followers
Foresight Diagnostics is the world’s most sensitive liquid biopsy minimal residual disease (MRD) test that detects the earliest hints of cancer relapse.